Gilead Sciences Reports Strong Performance and Promising Cell Therapy Plans in Q1 Earnings Call

Friday, 26 April 2024, 01:45

Gilead Sciences reported a strong first quarter performance in 2024, driven by growth across HIV, oncology, and liver disease businesses. The company highlighted exciting plans for expanding its industry-leading cell therapy program, including new trials and potential therapies for a range of solid tumors. With 54 active clinical programs and no major patent expiries through the decade, Gilead remains focused on disciplined execution and continued growth.
https://store.livarava.com/df126519-036f-11ef-a6c0-63e1980711b2.jpg
Gilead Sciences Reports Strong Performance and Promising Cell Therapy Plans in Q1 Earnings Call

Gilead Sciences Q1 2024 Earnings Call Highlights

Gilead Sciences reported a strong first quarter performance in 2024, driven by growth across HIV, oncology, and liver disease businesses.

Key Growth Drivers:

  • Total product sales, excluding Veklury, grew 6% year over year to $6.6 billion.
  • HIV product sales grew 4% year over year, driven by higher demand and favorable pricing dynamics in Europe.
  • Oncology product sales were up 18%, fueled by strong demand for Trodelvy and cell therapies.

Exciting Plans for Cell Therapy:

  • Plans to expand industry-leading cell therapy program with trials for a range of solid tumors.
  • Expectation of over a dozen oncology presentations, including late-breaking Phase 3 data at upcoming conferences.
  • Exploration of next-generation CAR-T constructs and innovative immunotherapy approaches.

Gilead remains focused on disciplined execution and growth opportunities across its diverse portfolio of therapies.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe